- Home
- BRTX vs SYBX Comparison
BRTX vs SYBX Comparison
Compare BRTX & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRTX
- SYBX
- Stock Information
- Founded
- BRTX 1997
- SYBX N/A
- Country
- BRTX United States
- SYBX United States
- Employees
- BRTX N/A
- SYBX N/A
- Industry
- BRTX Managed Health Care
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- BRTX Health Care
- SYBX Health Care
- Exchange
- BRTX Nasdaq
- SYBX Nasdaq
- Market Cap
- BRTX 10.7M
- SYBX 16.5M
- IPO Year
- BRTX N/A
- SYBX N/A
- Fundamental
- Price
- BRTX $1.58
- SYBX $1.24
- Analyst Decision
- BRTX Strong Buy
- SYBX Hold
- Analyst Count
- BRTX 1
- SYBX 1
- Target Price
- BRTX $18.00
- SYBX N/A
- AVG Volume (30 Days)
- BRTX 1.1M
- SYBX 13.1K
- Earning Date
- BRTX 03-28-2025
- SYBX 03-06-2025
- Dividend Yield
- BRTX N/A
- SYBX N/A
- EPS Growth
- BRTX N/A
- SYBX N/A
- EPS
- BRTX N/A
- SYBX N/A
- Revenue
- BRTX $377,000.00
- SYBX $8,000.00
- Revenue This Year
- BRTX $482.76
- SYBX N/A
- Revenue Next Year
- BRTX $212.24
- SYBX N/A
- P/E Ratio
- BRTX N/A
- SYBX N/A
- Revenue Growth
- BRTX 189.55
- SYBX N/A
- 52 Week Low
- BRTX $1.03
- SYBX $1.15
- 52 Week High
- BRTX $2.55
- SYBX $2.04
- Technical
- Relative Strength Index (RSI)
- BRTX 41.43
- SYBX 34.36
- Support Level
- BRTX $1.46
- SYBX $1.15
- Resistance Level
- BRTX $1.68
- SYBX $1.39
- Average True Range (ATR)
- BRTX 0.22
- SYBX 0.06
- MACD
- BRTX -0.01
- SYBX -0.01
- Stochastic Oscillator
- BRTX 25.81
- SYBX 32.73
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.